StayinFront expands services contract with biotechnology firm
StayinFront, a provider of CRM systems, has announced expanded agreement with a New Jersey-based global biotechnology firm to include a range of technical services to support its entire enterprise.
As a part of the expanded contract, StayinFront will offer extended hours of technical support across a range of applications for their home office colleagues.
StayinFront's technical staff will provide first tier phone and internet support to approximately 250 sales and marketing professionals on applications ranging from Microsoft Office to SAS, the company said.
StayinFront North America executive vice president and managing director Sam Barclay said they deliver a range of day-to-day, operational and technical services to ensure that our clients' business needs are met.
Related Insight
Suppliers Directory
FormPipe - Quality Management, CAPA Processes, SOP Management, FDA and GMP Compliance
FormPipe Software AB (publ) is an Enterprise Content Management (ECM) software company. FormPipe Software develop ECM products for structuring information and supply them to major companies, authorities and other organisations.
Automation > IT & Software > Suppliers
Labware - Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebooks (ELN) and Instrument Integration Software Products
LabWare is the world's leading specialist in Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebook (ELN) and instrument integration software products. LabWare was founded in 1988 and is headquartered in Wilmington, Delaware, US.
Automation > IT & Software > Suppliers
Infotehna Group - Pharmaceutical Software Solutions
Infotehna Group has been in the forefront of global providers of software solutions for the pharmaceutical industry for more than 20 years.
Automation > IT & Software > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
IT & Software Intelligence
Efficient Pharmacovigilance Process Based on Document Management
Published by Infotehna Group
Automation > IT & Software > White Papers
State and Federal “Sunshine Acts” Shift KOL Marketing Tactics
Published by Alliance Life Sciences Consulting Group, Inc.
Automation > IT & Software > White Papers
Healthcare Reform, Compliance, and Organizational Optimization
Published by Alliance Life Sciences Consulting Group, Inc.
Automation > IT & Software > White Papers
Laboras: Automated Behavior Recognition and Motion Tracking
Published by Metris
Automation > IT & Software > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.